Pacific Edge - Test sales up 43% in H119

Edison Investment Research - Pharmaceuticals & healthcare - Pacific Edge: Pacific Edge recently reported H119 results, including 43% growth in Cxbladder sales compared to H118. These sales exclude tests for patients covered by the US Centers for Medicare and Medicaid Services (CMS), which currently account for 47% of lab throughput. The company is in the process of gaining inclusion in the CMS's local coverage determination (LCD), which will enable reimbursement and negotiation for payment of more than 14,000 tests previously performed on patients covered by CMS.

ISIN: NZPEBE0002S1

Den vollständigen Artikel lesen ...